Daily Biotech Movers — 2026-09-24: Tools Rally to 52-Week Highs While Wednesday's Two Biggest Winners Hand It All Back

Thursday, September 24, 2026 was the mirror image of the session that preceded it, and then it was something else entirely. Across 572 tracked public biotech and life-sciences companies, 320 finished lower against 237 advancers — a decliner-to-advancer ratio of 1.35-to-1, a marked improvement on Wednesday’s 6.6-to-1, but still a day on which more names fell than rose. The median move was -0.54% and the mean -0.43%, with a standard deviation of 6.70% — the widest dispersion this desk has recorded this quarter, against Wednesday’s 6.24% on a far more directional tape. 108 companies moved at least 5% and 126 were anomaly-flagged once volume-only spikes are counted. Fifteen names closed exactly unchanged.

What makes the session interesting is what sat underneath those aggregates. The small-cap biotech index proxy closed higher, +0.55%, and the cap-weighted large-cap proxy finished ahead as well, so the sector made money at the index level on a day when the typical tracked name lost half a percent. The gap was not noise: it was a rally in life-science tools and platforms — Ginkgo Bioworks +18.95%, CareDx +16.70%, Twist Bioscience +15.93%, 10x Genomics +11.35%, Prime Medicine +10.54% — running at the same time as a second consecutive day of selling in small-cap clinical-stage equities, with Acadia Pharmaceuticals -11.84%, Viking Therapeutics -11.69%, Larimar Therapeutics -12.29%, Tvardi Therapeutics -18.94% and a 157x-volume collapse in aTyr Pharma (-10.02%) on the board. The macro backdrop was unchanged from the day before — the 10-year Treasury yield rose again to 5.163% and the S&P 500 finished marginally lower MarketWatch — Stock Market on Sept. 24, 2026; Reuters — S&P 500 ends marginally lower — which is precisely why the day is best read as rotation inside healthcare rather than a macro repricing.

The Distribution

Measure	September 24 reading
Tracked / priced	572
Directional moves	557 (237 up, 320 down), 15 unchanged
Up / down ratio	1.35-to-1 decliners
Mean / median	-0.43% / -0.54%
Standard deviation	6.70%
Average advancer / decliner	+3.58% / -3.42%
Price moves of at least 5%	108
Anomaly-flagged (incl. volume-only)	126
Stealth names (|move| < 3% on 3x+ volume)	4

Two features of that table matter. The first is the symmetry of the tails: the average advancer gained +3.58% and the average decliner lost -3.42%, so the day was not a liquidation — it was a cluster of violent single-name repricings in both directions, which is what a 6.70% standard deviation on a -0.54% median means. The second is that the index proxies disagree with the median, and they disagree because the tracked universe is not the index. Our universe is deliberately small-cap weighted: the largest single bucket, Small Molecule Pharma (n=152), fell -1.15%, Biologics (n=86) fell -1.02%, RNA, Peptide & Gene Therapy (n=27) fell -0.99%, and Devices — Miscellaneous (n=26) fell -2.76%. The winners’ side of the sector table is thinner but real: Genetics & Genomics +4.93% (n=7), Generic Drugs +3.59% (n=5), Diagnostics +1.75% (n=30), Non-Pharmaceutical Biotech +1.65% (n=20) and Antibodies +1.12% (n=42). The laggard is an artefact of one stock: Cannabis-related -8.33% (n=5) is Artelo Biosciences, a cannabinoid-therapeutics developer, dragging a five-name bucket.

The stealth set inverted relative to the two prior sessions. Four names cleared the filter — Traws Pharma (+1.37% on 307.76x), Boundless Bio (-2.96% on 5.20x), IN8bio (+2.75% on 4.53x) and Kyverna Therapeutics (-1.70% on 4.31x) — a mix of flat-to-up and flat-to-down prints on extreme turnover. On Wednesday the same filter produced five names that all closed flat to up while 84.7% of the universe fell; today it produced two of each, on a day when the tape itself was split. The single most extreme volume ratio on the board belongs to Traws Pharma at 307.76x on a +1.37% close — a $0.51 equity printing 28.3 million shares — which is the definition of mechanical turnover without a price verdict.

The 6 Classes of Mover Signal

1. Halt-release and reverse-split-adjacent mechanics. Present but not dominant. Silexion (-17.79% on 0.24x) is the cleanest example: a $0.2592 close on below-average volume, giving back part of the prior week’s +15.4% momentum run, in a company whose paper trail is a proxy seeking 175 million new shares and another reverse split. Scinai Immunotherapeutics (-14.14% on 0.06x) traded almost no shares and still lost seven times the median move — a book with no depth. Celularity (+15.64% on 0.05x) is the same phenomenon upward: a 1,000-to-1 imbalance between price and liquidity.

2. Single-stock clinical, regulatory or commercial catalyst. Present, and it supplied the day’s largest winner and two of its three largest losers. Surrozen (+107.86% on 65.30x) moved on the read-through of its IND submission for SZN-8141 in diabetic macular edema and the tranched capital it unlocks. Profusa (+41.46% on 28.76x) moved on a same-day regulatory-quality milestone — a positive decision from the EU notified body GMED on ISO 13485 certification of its quality management system, the gate in front of CE marking for its Lumee Oxygen Platform. On the losing side, Vistagen (-19.95%) published a same-day subgroup analysis from a programme the market had already bought, and Tvardi (-18.94% on 4.27x) published preclinical colitis data that the tape ignored in favour of a slide that had begun earlier in the week.

3. Buyout and strategic capital. Absent in its classic form. The closest event is the financing architecture inside Surrozen’s move: a $175 million raise structured so that a regulatory-progress milestone releases a further tranche — roughly $98.4 million by the market’s read AInvest — Surrozen Surges After IND Filing for SZN-8141. That is strategic capital arriving on an event calendar rather than a premium arriving from an acquirer, and it is repriced accordingly.

4. Sector rotation. Present, and the defining feature of the session — just not the rotation of the day before. Wednesday’s rotation was out of everything capital-hungry; Thursday’s was out of small-cap clinical-stage biotech and into life-science tools, diagnostics and platforms. CareDx closed above its previously recorded 52-week high, Twist Bioscience closed above its, 10x Genomics closed above its, and Ginkgo Bioworks gained 18.95% to sit 40% up the range it has traded over the past year. Meanwhile ARTL closed at roughly 1% of its 52-week range, VTGN at 2%, ATYR below its recorded low, TVRD at a new low, and Traws at 3%. One half of the sector is being financed at highs; the other half is being marked at lows.

5. Sell-the-news and prior-cycle profit-taking. Present, expensive, and unusually pure. Artelo (-30.92%) surrendered the bulk of Wednesday’s +76.14% patent-driven spike on average volume. Vistagen (-19.95%) gave back roughly two-fifths of its +46.54% spike on below-average volume after publishing the third increment of the same fasedienol story. Tvardi (-18.94%) extended a five-day decline to -23.7% on a day whose only company news was a mouse-model publication. Three different instruments, one conclusion: in this tape, holding a recent gain remained the most expensive position available.

6. Stealth accumulation and distribution. Present at four names, and directionally mixed — Traws (+1.37% on 307.76x), IN8bio (+2.75% on 4.53x) and Boundless Bio (-2.96% on 5.20x), Kyverna (-1.70% on 4.31x). The information here is the volume-to-price ratio, not the direction: a 307x print that leaves the price unchanged is a claim about who is trading, not about what the company is worth.

Top 3 Winners — What Drove Them

SRZN — Surrozen — +107.86% on 65.30x volume

Surrozen closed at $33.59 on 11,517,941 shares — 65.30x its 30-day average, against a $16.16 prior close, having traded between $16.50 and $35.86 — an intraday print above its previously recorded 52-week high of $35.00 — and finishing at 94% of its 52-week range. Signal class: Class 3 financing-milestone event riding a Class 2 regulatory-progress disclosure. The driver is the IND submission to the FDA for SZN-8141, a bifunctional FZD4-mediated Wnt agonist and VEGF antagonist antibody for diabetic macular edema Surrozen — Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema; Benzinga — Surrozen Gains Momentum as FDA Submission Opens Path for Lead Therapy; RTTNews — Surrozen Submits IND Application For SZN-8141 In Diabetic Macular Edema. The company said in the release that it expects to initiate the DUET Phase 1b/2a study in DME patients by year-end 2026, with initial data in the second half of 2027, and noted that a FZD4-mediated Wnt agonist monotherapy has already shown clinical proof of concept in the same pathway Surrozen — IND submission press release, September 8, 2026. The caution sits in the tape rather than the science: a stock with roughly 176,000 shares of normal daily turnover printing 65x volume and a $19.36 intraday range is a low-float repricing, and trading commentary attributed part of the spike to momentum flow arriving on top of a two-week-old disclosure QuiverQuant — Surrozen stock doubles as traders focus on IND progress and potential financing milestone; Tickeron — Why Is Surrozen (SRZN) Stock Up +103% Today?.

PFSA — Profusa — +41.46% on 28.76x volume

Profusa closed at $2.90 on 79,162,625 shares — 28.76x its 30-day average, against a $2.05 prior close, with five-day momentum at +15.2%. Signal class: Class 2 single-stock regulatory milestone, same-day and dated. On September 24 the company announced a positive decision from GMED — a notified body designated under the European Union Medical Device Regulation — on certification of its quality management system to ISO 13485, the quality gate that precedes CE marking for its Lumee Oxygen Platform, a continuous real-time tissue-oxygen monitor Profusa — Press Releases; FinancialContent / GlobeNewswire — Profusa Announces Significant Progress Towards Lumee Oxygen Platform CE Mark With ISO 13485 Certification Expected in Early October; MarketScreener — Profusa announces significant progress towards Lumee Oxygen Platform CE mark. The company said certification is expected to be finalised in early October, which is what gives the print its shape — a dated, binary checklist event rather than an open-ended narrative MarketChameleon — Profusa highlights ISO 13485 quality milestone as Lumee Oxygen Platform CE mark nears; Yahoo Finance — Profusa ISO 13485 Certification Decision Advances Lumee Oxygen Platform. The context a reader needs: this is a micro-cap that spent September repairing its own listing status, having disclosed a Nasdaq compliance determination on the bid-price rule earlier in the month RTTNews — Profusa (PFSA) company profile and disclosure history. A quality-system milestone is a real de-risking step toward European clearance — and it is also the cheapest kind of news a company with a regulatory calendar can produce.

BNR — Burning Rock Biotech — +20.07% on 3.28x volume

Burning Rock closed at $18.10 on 135,975 shares — 3.28x its 30-day average, against a $15.075 prior close, extending five-day momentum to +20.4% and sitting 32% up its 52-week range. Signal class: no clean same-day catalyst — thin-ADR momentum continuation. Nothing was published on September 24. The most recent disclosure is the September 10 second-quarter release: revenue of RMB134.7 million (US$19.9 million), down 9.3% year on year but up 24.8% sequentially, with in-hospital revenue growing 7.4% while central-lab and pharma research-service revenue declined, and a widened net loss of RMB18.4 million Burning Rock Biotech — Press Releases; TipRanks — Burning Rock Biotech posts Q2 2026 revenue decline but advances fast-track reviews for oncology NGS kits; ADVFN / GlobeNewswire — Burning Rock Reports Second Quarter 2026 Financial Results. The ADRs were already up 7.2% on September 16 on modestly above-average volume MarketBeat — Burning Rock Biotech Trading 7.2% Higher. With roughly 136,000 shares changing hands, a 20% session on the fifth consecutive up-day is more legible as a thin float repricing than as new information StockTitan — Burning Rock Biotech (BNR) overview and filing profile. Prior-cycle catalyst — flagged.

Top 3 Losers — What Drove Them

ARTL — Artelo Biosciences — -30.92% on 1.01x volume

Artelo closed at $5.05 on 1,053,089 shares — 1.01x its 30-day average, against a $7.31 prior close, leaving five-day momentum at +94.9% and the shares at roughly 1% of their 52-week range. Signal class: Class 5 sell-the-news — the give-back leg of Wednesday’s spike, with no fresh negative disclosure. The prior session took the shares as high as $15.73 intraday before they closed at less than half that level; today continued the same unwind Tickeron — Why Is Artelo Biosciences (ARTL) Stock Down -34.06% Today?. What is being repriced is a provisional patent application covering ART27.13, the company’s oral dual CB1/CB2 receptor agonist, for obesity as monotherapy and in combination with GLP-1 receptor agonists such as semaglutide Artelo Biosciences — Files New Provisional Patent Application Covering ART27.13 for Obesity; RTTNews via Nasdaq — Artelo Expands ART27.13 Patent Coverage After Obesity Study Findings. The underlying evidence is the DIO-2 diet-induced-obesity mouse study disclosed on September 16 — roughly 20% weight loss as monotherapy over four weeks, about 40% in combination, with a fat-mass share of roughly 80% versus 70% for semaglutide alone Artelo Biosciences — ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination. Three things separate this from a verdict on the science: it printed on average volume rather than distribution-scale turnover; the run-up it gave back was built on nonclinical data plus a filing; and the company’s disclosures put cash at roughly $4.2 million with a stated need to raise, which makes every post-spike session a referendum on dilution Artelo Biosciences — Investor News. Prior-cycle catalyst — flagged.

VTGN — Vistagen Therapeutics — -19.95% on 0.92x volume

Vistagen closed at $0.2949 on 20,315,737 shares — 0.92x its 30-day average, against a $0.3684 prior close, with five-day momentum still +59.8% and a close 2% up its 52-week range. Signal class: Class 5 sell-the-news on a same-day disclosure the market had already paid for. On September 24 the company issued a press release, filed as an 8-K, summarising positive exploratory efficacy data for fasedienol, its intranasal rapid-onset candidate, presented as a poster at Psych Congress 2026 — a potential efficacy signal in patients with very severe social anxiety disorder drawn from two double-blind, placebo-controlled public-speaking studies Vistagen Therapeutics — Form 8-K, September 24, 2026; Yahoo Finance — Vistagen Presents Fasedienol Subgroup Data in Severe Social Anxiety; TipRanks — VistaGen highlights Phase 3 data in severe social anxiety. The session being reversed was built on the September 22 8-K reporting preliminary positive data from the open-label extension of the PALISADE-4 Phase 3 study and a stated plan to meet the FDA this quarter — a disclosure that took the shares +46.54% on 740x volume Vistagen Therapeutics — Form 8-K, September 22, 2026; MarketChameleon — VTGN rises after fasedienol open-label extension shows 1.6% adverse-event discontinuations. Today’s item is a subgroup analysis from the same programme — exploratory, uncontrolled, and presented at a medical congress — a weaker instrument than the release that preceded it. The tell is volume: below average at 0.92x, in a stock that had traded 574 million shares two sessions earlier, which reads as a holder base stepping back rather than as a fundamental repricing StockTitan — Vistagen reports 31-point social anxiety score gain. Prior-cycle catalyst — flagged.

TVRD — Tvardi Therapeutics — -18.94% on 4.27x volume

Tvardi closed at $1.07 on 609,523 shares — 4.27x its 30-day average, against a $1.32 prior close, extending five-day momentum to -23.7% and printing a new 52-week low below its previously recorded $1.25 floor. Signal class: Class 5 prior-cycle continuation — the day’s disclosure was a preclinical publication, and the decline has no supporting company news. On September 24 the company announced publication of preclinical data evaluating its STAT3 inhibitor TTI-101 in the International Journal of Molecular Sciences, covering drug distribution and activity in a chronic colitis model — colon concentrations roughly 8-fold plasma levels and more than 20 times the STAT3 IC50 — as support for investigating STAT3 inhibition in inflammatory bowel disease, including ulcerative colitis StockTitan — New preclinical data further support potential for Tvardi’s STAT3 inhibitors in ulcerative colitis; GlobeNewswire via Business Insider — New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis. Nothing in it is negative, which is the point: the loss runs in the opposite direction to the day’s information and in the same direction as the prior week MarketScreener — Tvardi Therapeutics announces publication of preclinical data evaluating its STAT3 inhibitor; MarketChameleon — TVRD press releases. The structural context is that Tvardi’s equity story is anchored on TTI-101 clinical data, and commentary has framed any deviation from that timeline as an immediate volatility event in a thinly capitalised issuer AInvest — Tvardi Therapeutics: H1 2026 TTI-101 data is the only path to survival; StreetInsider — Tvardi publishes preclinical STAT3 inhibitor data for ulcerative colitis. Prior-cycle catalyst — flagged.

The Cross-Cutting Pattern

The pattern is a rotation, not a repricing. On Wednesday every bucket fell and the only names bid were two microcaps too small to be de-risked; on Thursday the capital that came back into healthcare went specifically into tools, diagnostics and platforms, and specifically not into clinical-stage small caps. The evidence is the divergence between the index-level and median-level readings: the sector proxy closed +0.55% on a day when the median tracked company fell -0.54%, and a 6.70% standard deviation on a -0.54% median is not a market moving together — it is a market moving in two directions at once. The tools complex provided one direction, with CareDx, Twist Bioscience and 10x Genomics all closing above previously recorded 52-week highs and Ginkgo Bioworks up 18.95%; the clinical small-cap complex provided the other, with ARTL at 1% of range, VTGN at 2%, ATYR and TVRD at new lows, and Small Molecule Pharma (n=152) down -1.15% as the largest bucket on the board.

The second theme is what yesterday’s winners cost their holders. Artelo (-30.92%) and Vistagen (-19.95%) were the two largest gainers of the prior session, at +76.14% and +46.54%; they were the two largest losers of this one. Both gave back ground on average or below-average volume — not the signature of institutions selling a thesis, but of a momentum bid that simply stopped arriving. Add Tvardi (-18.94%, five-day -23.7%) and Silexion (-17.79%, still +15.4% on five days), and the day’s losing tail is dominated by names that had recently run rather than names that had recently disappointed. In a market where the 10-year yield is still pushing higher, the marginal buyer is paying for dated regulatory checkpoints and platform exposure, and not for speculative spikes in $5.05 and $0.29 equities.

The third theme is the quality of the day’s one large win. Surrozen’s +107.86% is the print of the session, and it is a financing-architecture event as much as a scientific one: an IND submission that the company had already announced in early September, priced by a market that reads it as unlocking a tranche of committed capital, in an equity with roughly 168,000 shares of normal daily turnover. Profusa’s +41.46%, by contrast, is the cleaner signal of the two — a notified-body decision with a stated completion window in early October — and it landed in a micro-cap that had spent the month repairing its listing status. One of these is a fact with a date on it; the other is a fact with a float attached.

The 5 Data Points That Matter

1. Percentage change versus the tape. With a -0.54% median, the six leaders and laggards are all 10-point-plus divergences. But the sector-relative gaps are what isolate the idiosyncratic moves. SRZN +107.86% and PFSA +41.46% are on the wrong side of a tape that fell at the median — genuine decoupling, in both cases tied to a dated disclosure. ARTL -30.92% against Cannabis-related -8.33% (n=5) is a 23-point inversion inside a bucket that is substantially Artelo itself. VTGN -19.95% against Small Molecule Pharma -1.15% (n=152) and TVRD -18.94% against the same bucket are 19- and 18-point inversions in a group that barely moved — which is what a positioning unwind looks like, as distinct from the 108-point gap that Surrozen’s financing milestone produced.

2. Volume ratio. The heaviest ratios are on both edges and in the middle. Traws Pharma at 307.76x and aTyr Pharma at 157.67x — the latter on 129.9 million shares for a $0.34 stock — are turnover events without a clear catalyst. SRZN at 65.30x, HCWB at 47.71x (+14.46%), PFSA at 28.76x and VKTX at 7.15x are volume confirming that something was repriced. And the two biggest losers are the tell that matters: ARTL at 1.01x and VTGN at 0.92x fell 31% and 20% on no unusual volume at all — declines that are simply the absence of a bid, not the arrival of a seller.

3. Five-day momentum. This column separates an event from a trend, and today it mostly says “reversal”. ARTL’s +94.9% against a -30.92% day is a spike being unwound inside its own week. VTGN’s +59.8% against -19.95% is the same construction. VKTX’s +41.1% against -11.69% is a name that had run and was sold into strength on 7.15x volume. TVRD’s -23.7% against -18.94% is the opposite: trend continuing, with the biggest single-day loss arriving inside a decline that was already underway. Only BNR’s +20.4% and DNA’s +21.5% are consistent with continuation, and in BNR’s case there is no catalyst to continue on.

4. Position in range and absolute price. The tools rally is a range-high event: CareDx and Twist Bioscience closed above previously recorded 52-week highs, 10x Genomics did the same, and SRZN printed $35.86 intraday against a recorded high of $35.00. The clinical tail is the mirror: ARTL at ~1% of its 52-week range, VTGN at ~2%, Traws at ~3%, ATYR and TVRD at or below their recorded lows. Five of the day’s six leaderboard names are sub-$35 equities and one trades below $0.30; the outlier is SRZN at $33.59, which is expensive only relative to where it started the session.

5. Cash and dilution context. This is the differentiator and it explains most of the losing tail. ARTL has roughly $4.2 million of disclosed cash and a stated need to raise against a pipeline whose obesity story rests on mouse data and a patent filing. TVRD is a $1.07 equity with a clinical timeline carrying the whole equity story. SLXN is asking shareholders for 175 million new shares and another reverse split. Against that, PFSA’s milestone is a regulatory-quality event that costs nothing to file and shortens the path to a European clearance, and SRZN’s is a milestone that releases committed capital rather than consuming it. That asymmetry — capital released versus capital required — is the cleanest single-day explanation available for which names held and which did not.

The five-point summary: read SRZN as a low-float financing-milestone repricing on a two-week-old IND disclosure; read PFSA as a dated regulatory-quality checkpoint in a micro-cap that has just finished repairing its listing status; read BNR as thin-ADR momentum with no same-day news; read ARTL as a nonclinical patent spike being unwound on average volume; read VTGN as the same unwind applied to a fasedienol story the market had already paid for; and read TVRD as a sub-$1 equity trending to a new low in the opposite direction to its own headlines.

What This Synthesis Will and Won’t Tell You

This is a one-day reading and should be read as one. It tells you what moved and why: the 126 anomaly-flagged names, the six data-defined top movers, the class of signal behind each, and the cross-cutting pattern — a rotation inside healthcare in which the index-level proxies rose while the median tracked company fell, a tools and diagnostics complex (Diagnostics +1.75% (n=30), Genetics & Genomics +4.93% (n=7)) rallied to 52-week highs, the small-cap clinical complex (Small Molecule Pharma -1.15%, n=152) kept bleeding, and the prior session’s two largest winners became this session’s two largest losers on no unusual volume. It does not tell you what happens next: whether the tools bid persists past a session in which the 10-year yield still rose, whether Surrozen’s IND progresses to the DUET study by year-end and whether the financing tranche it appears to unlock is drawn on schedule; whether Profusa’s ISO 13485 certification is finalised in early October as the company expects and converts into CE marking; whether Artelo’s ART27.13 obesity programme reaches a human trial rather than a further patent filing; whether Vistagen’s planned FDA meeting converts a subgroup signal into a viable regulatory path for fasedienol after PALISADE-4 missed; or whether Tvardi’s TTI-101 timeline holds.

The honest limits: the catalyst investigation covers the six data-defined top movers only. The rest of the anomaly board — CytoSorbents -16.33%, LeonaBio -15.11%, Scinai -14.14%, Actuate -12.52%, Larimar -12.29%, Acadia -11.84%, Viking -11.69% on the downside, and Ginkgo +18.95%, CareDx +16.70%, Twist +15.93%, Celularity +15.64%, HCW Biologics +14.46% on the upside — carries stories that are noted but not deep-dived, and several genuinely large moves sit outside the data-defined top three on either side. Two of the six leaderboard names had no clean same-day catalyst and this synthesis labels them mechanical and prior-cycle rather than inventing narratives for them. Three of the six are sub-$2 equities where a single session’s percentage move is a statement about a float, not a business. And a -0.54% median on 320 decliners alongside a +0.55% index proxy says more about which part of the sector owns the marginal dollar than about the clinical or commercial prospects of the companies involved: this was capital choosing platforms over speculation, not the market re-rating science.

---

This is editorial analysis, not investment advice. Single-day returns reflect regular-session closing prices on 2026-09-24 and will change with market conditions, clinical readouts, financing terms, and regulatory events. Microcap and clinical-stage names can experience rapid reversals; readers should review the underlying disclosures before drawing conclusions about momentum durability.

Generated 2026-09-24 PT (post-market, after the 4 PM ET close). Market data compiled from public quote and historical market-data feeds; sector categorization from public company filings and listings; company backgrounds compiled from public investor disclosures and press releases. For the prior synthesis, see Daily Biotech Movers — 2026-09-23.